阿普唑仑对健康正常成年人精神运动表现和模拟驾驶的次日残留效应。

IF 2.4 3区 医学 Q3 PHARMACOLOGY & PHARMACY Experimental and clinical psychopharmacology Pub Date : 2024-11-14 DOI:10.1037/pha0000746
Stevie C Roszkowski, Shanna Babalonis, Marion A Coe, Paul A Nuzzo, Michelle R Lofwall, Laura C Fanucchi, Sharon L Walsh
{"title":"阿普唑仑对健康正常成年人精神运动表现和模拟驾驶的次日残留效应。","authors":"Stevie C Roszkowski, Shanna Babalonis, Marion A Coe, Paul A Nuzzo, Michelle R Lofwall, Laura C Fanucchi, Sharon L Walsh","doi":"10.1037/pha0000746","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of drugged driving has increased in the United States. Some drugged driving may be unintentional as prescription medications used as sleeping aids, like zolpidem, cause impairment after the predicted duration of therapeutic action has elapsed. The aim of this study was to determine if nighttime administration of alprazolam, a drug commonly prescribed off-label as a sleeping aid, impacts driving performance the following day. Participants were healthy adults (<i>n</i> = 15) who completed a double-blind, double-dummy, within-subjects inpatient study examining the effects of nighttime administration of alprazolam (0.5, 1, and 2 mg), zolpidem (10 mg), and placebo on driving performance the following day. Alprazolam (1 mg; morning) and zolpidem (nighttime) both served as positive control conditions. Driving simulator measures, cognitive and psychomotor tasks, and questionnaires querying drug effects were collected the afternoon before drug administration and for 5.5 hr the next day and analyzed using symmetry and mixed-model approaches. Morning alprazolam significantly impaired driving performance. Driving impairment was observed up to 12.5 hr after nighttime alprazolam 2 mg and for 8.5 hr after nighttime zolpidem 10 mg. Participant reports on driving ability indicated that they were not aware of their level of impairment. These results suggest that alprazolam used before bed may pose a yet unrecognized public safety risk in the form of next-day drugged driving. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Residual next-day effects of alprazolam on psychomotor performance and simulated driving in healthy normal adults.\",\"authors\":\"Stevie C Roszkowski, Shanna Babalonis, Marion A Coe, Paul A Nuzzo, Michelle R Lofwall, Laura C Fanucchi, Sharon L Walsh\",\"doi\":\"10.1037/pha0000746\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The prevalence of drugged driving has increased in the United States. Some drugged driving may be unintentional as prescription medications used as sleeping aids, like zolpidem, cause impairment after the predicted duration of therapeutic action has elapsed. The aim of this study was to determine if nighttime administration of alprazolam, a drug commonly prescribed off-label as a sleeping aid, impacts driving performance the following day. Participants were healthy adults (<i>n</i> = 15) who completed a double-blind, double-dummy, within-subjects inpatient study examining the effects of nighttime administration of alprazolam (0.5, 1, and 2 mg), zolpidem (10 mg), and placebo on driving performance the following day. Alprazolam (1 mg; morning) and zolpidem (nighttime) both served as positive control conditions. Driving simulator measures, cognitive and psychomotor tasks, and questionnaires querying drug effects were collected the afternoon before drug administration and for 5.5 hr the next day and analyzed using symmetry and mixed-model approaches. Morning alprazolam significantly impaired driving performance. Driving impairment was observed up to 12.5 hr after nighttime alprazolam 2 mg and for 8.5 hr after nighttime zolpidem 10 mg. Participant reports on driving ability indicated that they were not aware of their level of impairment. These results suggest that alprazolam used before bed may pose a yet unrecognized public safety risk in the form of next-day drugged driving. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>\",\"PeriodicalId\":12089,\"journal\":{\"name\":\"Experimental and clinical psychopharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and clinical psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1037/pha0000746\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1037/pha0000746","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

在美国,毒驾的发生率有所上升。由于唑吡坦等作为助眠药物的处方药会在预计的治疗作用持续时间过后对驾驶能力造成损害,因此有些药后驾驶可能是无意的。本研究旨在确定夜间服用阿普唑仑(一种常用的非标签处方助眠药物)是否会影响第二天的驾驶表现。参与者均为健康成年人(n = 15),他们完成了一项双盲、双假、受试者内住院研究,考察了夜间服用阿普唑仑(0.5、1 和 2 毫克)、唑吡坦(10 毫克)和安慰剂对次日驾驶表现的影响。阿普唑仑(1 毫克,早晨)和唑吡坦(夜间)均作为阳性对照条件。在服药前一天下午和第二天的5.5小时内收集了驾驶模拟器测量结果、认知和精神运动任务以及询问药物影响的问卷,并采用对称和混合模型方法进行了分析。早晨服用阿普唑仑会明显影响驾驶能力。夜间服用阿普唑仑 2 毫克后 12.5 小时内和夜间服用唑吡坦 10 毫克后 8.5 小时内均观察到驾驶能力受损。参试者对驾驶能力的报告表明,他们并未意识到自己的驾驶能力受损程度。这些结果表明,睡前服用阿普唑仑可能会造成一种尚未认识到的公共安全风险,即第二天的吸毒驾驶。(PsycInfo Database Record (c) 2024 APA,保留所有权利)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Residual next-day effects of alprazolam on psychomotor performance and simulated driving in healthy normal adults.

The prevalence of drugged driving has increased in the United States. Some drugged driving may be unintentional as prescription medications used as sleeping aids, like zolpidem, cause impairment after the predicted duration of therapeutic action has elapsed. The aim of this study was to determine if nighttime administration of alprazolam, a drug commonly prescribed off-label as a sleeping aid, impacts driving performance the following day. Participants were healthy adults (n = 15) who completed a double-blind, double-dummy, within-subjects inpatient study examining the effects of nighttime administration of alprazolam (0.5, 1, and 2 mg), zolpidem (10 mg), and placebo on driving performance the following day. Alprazolam (1 mg; morning) and zolpidem (nighttime) both served as positive control conditions. Driving simulator measures, cognitive and psychomotor tasks, and questionnaires querying drug effects were collected the afternoon before drug administration and for 5.5 hr the next day and analyzed using symmetry and mixed-model approaches. Morning alprazolam significantly impaired driving performance. Driving impairment was observed up to 12.5 hr after nighttime alprazolam 2 mg and for 8.5 hr after nighttime zolpidem 10 mg. Participant reports on driving ability indicated that they were not aware of their level of impairment. These results suggest that alprazolam used before bed may pose a yet unrecognized public safety risk in the form of next-day drugged driving. (PsycInfo Database Record (c) 2024 APA, all rights reserved).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.20
自引率
8.70%
发文量
164
审稿时长
6-12 weeks
期刊介绍: Experimental and Clinical Psychopharmacology publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse.
期刊最新文献
Evaluating the human abuse potential of concurrent use of electronic cigarettes and low nicotine cigarettes among adults who smoke. Residual next-day effects of alprazolam on psychomotor performance and simulated driving in healthy normal adults. Efficacy and safety of balovaptan for posttraumatic stress disorder: A randomized, placebo-controlled trial. A behavioral choice analysis of the role of life events during early nonabstinent natural recovery from alcohol use disorder. An experimental investigation into the impact of acute stress on alcohol craving.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1